The HERceptin® Adjuvant (HERA) Trial is a large-scale international clinical trial designed to determine if earlier use of the breast cancer drug Herceptin® (trastuzumab) can increase the length of survival without cancer recurrence in women whose early breast cancer has been diagnosed as HER2 positive. The Breast International Group (BIG) and F. Hoffmann-La Roche (Roche) are collaborating to conduct the HERA Trial.

To be eligible to participate in the trial patients must: (i)be diagnosed with primary breast cancer (ii) have been diagnosed as strongly HER2-positive (iii)have completed a course of standard systematic chemotherapy (standard chemotherapy administered before or after surgery) prior to enrolment.

It appears that the HERA trial is being conducted entirely outside the U.S.